Margaret Warner speaks with Dr. Anthony Fauci of the National Institute of Allergy and Infectious Disease about a new H1N1 flu vaccine.
Read the Full Transcript
Since the swine flu outbreak began last spring and spread to more than 100 countries, there has been a race to create an effective vaccine. In the U.S., H1N1, as it's called, infected more than a million people and caused about 600 deaths.
The flu threat diminished over the summer here, but it never went away, and now it's returned for a new season. Already, it's been detected in all 50 states and is widespread in the Southeast, plus Maryland, Oklahoma, Arizona, and Alaska.
Early on, the U.S. contracted to buy 195 million doses of the vaccine. Unknown at the time was: Would it be effective, would it be ready in time and in sufficient quantities?
Today, there was some good news on the vaccine front. Clinical trials show that just one dose will be effective for most adults who need it.
Dr. Anthony Fauci is head of the National Institute of Allergy and Infectious Diseases, which has overseen the government trials, and he joins us from the National Institutes of Health tonight.
And, Dr. Fauci, welcome. Thanks for joining us.
DR. ANTHONY FAUCI:
It's good to be here.
So how important is this news today, in terms of how well protected Americans will be from the H1N1?